Prevention and treatment of side-effects of systemic treatment: Bone loss

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Body, J J ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bisphosphonate; Bone; Breast cancer; Denosumab; Osteoporosis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTIANDROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LETROZOLE; LEUPRORELIN; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

AGING; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIETARY INTAKE; DISEASE SEVERITY; FRACTURE; HIP FRACTURE; HUMAN; LIFESTYLE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; VERTEBRA FRACTURE;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 78649356077     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq422     Document Type: Conference Paper

References (44)

1. Hoff AO, Gagel RF. Osteoporosis in breast and prostate cancer survivors. Oncology 2005; 19: 651-658.
2. Body JJ, Bergmann P, Boonen S et al. Management of cancer treatment-induced bone loss in early breast and prostatic cancer - a consensus paper of the Belgian Bone Club. Osteoporos Int 2007; 18: 1439-1450.
3. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S-17S.
4. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009; 69: 73-82.
5. Bruning PF, Pit MJ, de Jong-Bakker M et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990; 61: 308-310.
6. Hadji P, Ziller M, Maskow C et al. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in premenopausal women with breast cancer. Eur J Cancer 2009; 45: 3205-3212.
7. Jonat W, Kaufmann M, Sauerbrei W et al. Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635.
8. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84.
9. McCloskey EV. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006; 42: 1044-1051.
10. Goss PE, Qi S, Cheung AM, Hu H et al. Effects of the F(7) steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004; 10: 5717-5723.
11. McCloskey EV, Hannon RA, Lakner G et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007; 43: 2523-2531.
12. Eastell R, Hannon RA, Cuzick J et al. on behalf of the ATAC Trialists' Group. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21: 1215-1223.
13. Geisler J, Lonning PE, Krag LE et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomized placebo-controlled study. Eur J Cancer 2006; 42: 2968-2975.
14. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
15. Rabaglio M, Sun Z, Price KN et al. BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009; 20: 1489-1498.
16. Coombes RC, Kilburn LS, Snowdon CF et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570.
17. Smith MR, Boyce SP, Moyneur E et al. Risk of clinical fracture after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-139.
18. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
19. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol 2008; 26: 1051-1057.
20. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416.
21. Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
22. Coombes RC, Hall E, Gibson LJ et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
23. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
24. Kaufmann M, Jonat W, Hilfrich J et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007; 25: 2664-2670.
25. Hershman DL, McMahon DJ, Crew KD et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 2010; 95: 559-566.
26. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Austrian Breast and Colorectal Cancer Study Group. Zoledronic acid prevents cancer treatmentinduced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-828.
27. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9: 840-849.
28. Brufsky AM, Bosserman LD, Caradonna RR et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009; 9: 77-85.
29. Lester JE, Dodwell D, Purohit OP et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336-6342.
30. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitorinduced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28: 967-975.
31. Ellis GK, Bone HG, Chlebowski R et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009; 118: 81-87.
32. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
33. Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
34. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042.
35. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416-424.
36. Smith MR, Egerdie B, Herná ndez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
37. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004; 31: 331-352.
38. Oefelein MG, Resnick MI. The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am 2004; 31: 313-319.
39. Oefelein MG, Ricchuiti V, Conrad W et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-1728.
40. Malcolm JB, Derweesh IH, Kincade MC et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 2007; 14: 3551-3559.
41. Greenspan SL, Nelson JB, Trump DL et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008; 26: 4426-4434.
42. Smith MR, Malkowicz SB, Chu F et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008; 179: 152-155.
43. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001; 28(Suppl 11): 49-53.
44. Bilezikian JP. Osteonecrosis of the jaw - do bisphosphonates pose a risk? N Engl J Med 2006; 355: 2278-2281.